Hyperbaric Oxygen Treatment Improves Hearing Level Attenuating TLR4/NF-κB Mediated Inflammation in Sudden Sensorineural Hearing Loss Patients.

Xue Hua LIU; Fang LIANG; Xing Yuan JIA; Lin ZHAO; Yan ZHOU; Jing YANG

Return

Hyperbaric Oxygen Treatment Improves Hearing Level Attenuating TLR4/NF-κB Mediated Inflammation in Sudden Sensorineural Hearing Loss Patients.

Author: Xue Hua LIU ¹ ; Fang LIANG ¹ ; Xing Yuan JIA ² ; Lin ZHAO ³ ; Yan ZHOU ² ; Jing YANG ¹
Author Information

1. Department of Hyperbaric Oxygen Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
2. Institute of Basic Medicine Sciences, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
3. Department of Hyperbaric Oxygen Medicine, Beijing Pinggu Hospital, Beijing 101200, China.
Publication Type:Journal Article
Keywords: Hyperbaric oxygen treatment; Nuclear factor-kB; Sudden sensorineural hearing loss; Toll-like receptor 4
MeSH: Adolescent; Adult; Aged; China; Female; Hearing Loss, Sensorineural; therapy; Hearing Loss, Sudden; therapy; Humans; Hyperbaric Oxygenation; Inflammation; genetics; therapy; Male; Middle Aged; NF-kappa B p50 Subunit; genetics; metabolism; Toll-Like Receptor 4; genetics; metabolism; Young Adult
From: Biomedical and Environmental Sciences 2020;33(5):331-337
CountryChina
Language:English
Abstract: Objective:Hyperbaric oxygen treatment (HBOT) has demonstrated efficacy in improving hearing levels of patients with idiopathic sudden sensorineural hearing loss (ISSHL); however, the underlying mechanisms are not well understood. HBOT alleviates the inflammatory response, which is mediated by Toll-like receptor (TLR) 4 and nuclear factor (NF)-κB. In this study we investigated whether HBOT attenuates inflammation in ISHHL patients alteration of TLR4 and NF-κB expression.
Methods:ISHHL patients ( = 120) and healthy control subjects ( = 20) were enrolled in this study. Patients were randomly divided into medicine group treated with medicine only ( = 60) and HBO group receiving both HBOT and medicine ( = 60). Audiometric testing was performed pre- and post-treatment. TLR4, NF-кB, and TNF-α expression in peripheral blood of ISSHL patients and healthy control subjects was assessed by ELISA before and after treatment.
Results:TLR4, NF-κB, and TNF-α levels were upregulated in ISSHL patients relative to healthy control subjects; the levels were decreased following treatment and were lower in the HBO group than that in the medicine group post-treatment ( < 0.05 and < 0.01).
Conclusion:HBOT alleviates hearing loss in ISSHL patients by suppressing the inflammatory response induced by TLR4 and NF-κB signaling.